Stefan K. Barta
· MD, MSUniversity of Pennsylvania · Rehabilitation Medicine
Active 1999–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Stefan K. Barta, MD, MS, is an Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania and serves as the Director of the T-cell Lymphoma Program at UPenn. His clinical expertise includes T-cell lymphomas, HIV-associated lymphomas, and cutaneous lymphomas. His research focuses on HIV-related lymphomas, T-cell lymphomas, and cutaneous lymphomas, contributing to the understanding and treatment of these hematologic malignancies. Dr. Barta's work involves both clinical practice and research, aiming to improve outcomes for patients with lymphoma through innovative therapies and comprehensive studies.
Research topics
- Internal medicine
- Medicine
- Pathology
- Cancer research
- Immunology
- Oncology
Selected publications
American Journal of Hematology · 2021-03-04 · 388 citations
reviewOpen accessSenior authorCorrespondingDiffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therapy and can achieve long-term disease control in nearly 90% of patients presenting with limited-stage and in up to 60% of those presenting with advanced stages. Advances on the understanding of the genetic landscape and molecular features of DLBCL have id…
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine · 2024 · 250 citations
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 161 citations
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the…
The Lancet Haematology · 2020-08-24 · 141 citations
articleOpen accessNCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Journal of the National Comprehensive Cancer Network · 2020 · 61 citations
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional…
Frequent coauthors
- 235 shared
Daniel J. Landsburg
- 227 shared
Jakub Svoboda
University of Pennsylvania
- 225 shared
Stephen J. Schuster
University of Pennsylvania
- 210 shared
Sunita D. Nasta
University of Pennsylvania
- 197 shared
Elise A. Chong
Hospital of the University of Pennsylvania
- 172 shared
James N. Gerson
University of Pennsylvania
- 127 shared
Marco Ruella
University of Pennsylvania
- 101 shared
Narendranath Epperla
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Labs
T-cell Lymphoma Program, UPennPI
Similar researchers at University of Pennsylvania
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Stefan K. Barta
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup